These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 17548673)
1. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Allen NE; Key TJ; Appleby PN; Travis RC; Roddam AW; Rinaldi S; Egevad L; Rohrmann S; Linseisen J; Pischon T; Boeing H; Johnsen NF; Tjønneland A; Grønbaek H; Overvad K; Kiemeney L; Bueno-de-Mesquita HB; Bingham S; Khaw KT; Tumino R; Berrino F; Mattiello A; Sacerdote C; Palli D; Quirós JR; Ardanaz E; Navarro C; Larrañaga N; Gonzalez C; Sanchez MJ; Trichopoulou A; Travezea C; Trichopoulos D; Jenab M; Ferrari P; Riboli E; Kaaks R Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1121-7. PubMed ID: 17548673 [TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. Chan JM; Stampfer MJ; Ma J; Gann P; Gaziano JM; Pollak M; Giovannucci E J Natl Cancer Inst; 2002 Jul; 94(14):1099-106. PubMed ID: 12122101 [TBL] [Abstract][Full Text] [Related]
3. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Platz EA; Pollak MN; Leitzmann MF; Stampfer MJ; Willett WC; Giovannucci E Cancer Causes Control; 2005 Apr; 16(3):255-62. PubMed ID: 15947877 [TBL] [Abstract][Full Text] [Related]
4. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Woodson K; Tangrea JA; Pollak M; Copeland TD; Taylor PR; Virtamo J; Albanes D Cancer Res; 2003 Jul; 63(14):3991-4. PubMed ID: 12873996 [TBL] [Abstract][Full Text] [Related]
5. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Li L; Yu H; Schumacher F; Casey G; Witte JS Cancer Causes Control; 2003 Oct; 14(8):721-6. PubMed ID: 14674736 [TBL] [Abstract][Full Text] [Related]
6. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: A nested case-control study in large scale cohort study in Japan. Mikami K; Ozasa K; Nakao M; Miki T; Hayashi K; Watanabe Y; Mori M; Sakauchi F; Washio M; Kubo T; Suzuki K; Wakai K; Nakachi K; Tajima K; Ito Y; Inaba Y; Tamakoshi A; Asian Pac J Cancer Prev; 2009 Dec; 10 Suppl():57-61. PubMed ID: 20553083 [TBL] [Abstract][Full Text] [Related]
7. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. Stattin P; Rinaldi S; Biessy C; Stenman UH; Hallmans G; Kaaks R J Clin Oncol; 2004 Aug; 22(15):3104-12. PubMed ID: 15284261 [TBL] [Abstract][Full Text] [Related]
8. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. Stattin P; Bylund A; Rinaldi S; Biessy C; Déchaud H; Stenman UH; Egevad L; Riboli E; Hallmans G; Kaaks R J Natl Cancer Inst; 2000 Dec; 92(23):1910-7. PubMed ID: 11106682 [TBL] [Abstract][Full Text] [Related]
9. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Douglas JB; Silverman DT; Pollak MN; Tao Y; Soliman AS; Stolzenberg-Solomon RZ Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2298-306. PubMed ID: 20699371 [TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. Wolk A; Mantzoros CS; Andersson SO; Bergström R; Signorello LB; Lagiou P; Adami HO; Trichopoulos D J Natl Cancer Inst; 1998 Jun; 90(12):911-5. PubMed ID: 9637140 [TBL] [Abstract][Full Text] [Related]
11. IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Rinaldi S; Peeters PH; Berrino F; Dossus L; Biessy C; Olsen A; Tjonneland A; Overvad K; Clavel-Chapelon F; Boutron-Ruault MC; Téhard B; Nagel G; Linseisen J; Boeing H; Lahmann PH; Trichopoulou A; Trichopoulos D; Koliva M; Palli D; Panico S; Tumino R; Sacerdote C; van Gils CH; van Noord P; Grobbee DE; Bueno-de-Mesquita HB; Gonzalez CA; Agudo A; Chirlaque MD; Barricarte A; Larrañaga N; Quiros JR; Bingham S; Khaw KT; Key T; Allen NE; Lukanova A; Slimani N; Saracci R; Riboli E; Kaaks R Endocr Relat Cancer; 2006 Jun; 13(2):593-605. PubMed ID: 16728585 [TBL] [Abstract][Full Text] [Related]
12. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Yu H; Nicar MR; Shi R; Berkel HJ; Nam R; Trachtenberg J; Diamandis EP Urology; 2001 Mar; 57(3):471-5. PubMed ID: 11248622 [TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Chokkalingam AP; Pollak M; Fillmore CM; Gao YT; Stanczyk FZ; Deng J; Sesterhenn IA; Mostofi FK; Fears TR; Madigan MP; Ziegler RG; Fraumeni JF; Hsing AW Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):421-7. PubMed ID: 11352850 [TBL] [Abstract][Full Text] [Related]
14. Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Rohrmann S; Grote VA; Becker S; Rinaldi S; Tjønneland A; Roswall N; Grønbæk H; Overvad K; Boutron-Ruault MC; Clavel-Chapelon F; Racine A; Teucher B; Boeing H; Drogan D; Dilis V; Lagiou P; Trichopoulou A; Palli D; Tagliabue G; Tumino R; Vineis P; Mattiello A; Rodríguez L; Duell EJ; Molina-Montes E; Dorronsoro M; Huerta JM; Ardanaz E; Jeurnink S; Peeters PH; Lindkvist B; Johansen D; Sund M; Ye W; Khaw KT; Wareham NJ; Allen NE; Crowe FL; Fedirko V; Jenab M; Michaud DS; Norat T; Riboli E; Bueno-de-Mesquita HB; Kaaks R Br J Cancer; 2012 Feb; 106(5):1004-10. PubMed ID: 22315049 [TBL] [Abstract][Full Text] [Related]
15. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Chen C; Lewis SK; Voigt L; Fitzpatrick A; Plymate SR; Weiss NS Cancer; 2005 Jan; 103(1):76-84. PubMed ID: 15540247 [TBL] [Abstract][Full Text] [Related]
16. Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004. Nimptsch K; Platz EA; Pollak MN; Kenfield SA; Stampfer MJ; Willett WC; Giovannucci E Int J Cancer; 2011 Feb; 128(3):660-7. PubMed ID: 20473871 [TBL] [Abstract][Full Text] [Related]
17. Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study. Mucci LA; Stark JR; Pollak MN; Li H; Kurth T; Stampfer MJ; Ma J Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):484-91. PubMed ID: 20142246 [TBL] [Abstract][Full Text] [Related]
18. Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. Cao Y; Nimptsch K; Shui IM; Platz EA; Wu K; Pollak MN; Kenfield SA; Stampfer MJ; Giovannucci EL Int J Cancer; 2015 May; 136(10):2418-26. PubMed ID: 25348852 [TBL] [Abstract][Full Text] [Related]
19. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia. Aksoy Y; Aksoy H; Bakan E; Atmaca AF; Akçay F Urol Int; 2004; 72(1):62-5. PubMed ID: 14730168 [TBL] [Abstract][Full Text] [Related]
20. Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Peeters PH; Lukanova A; Allen N; Berrino F; Key T; Dossus L; Rinaldi S; van Gils CH; Bueno-de-Mesquita HB; Boeing H; Schulz M; Chang-Claude J; Linseisen J; Panico S; Sacerdote C; Palli D; Tumino R; Trichopoulou A; Trichopolos D; Bamia C; Larranaga N; Ardanaz E; Pera G; Quirós JR; Martínez-García C; Navarro C; Bingham SA; Khaw KT; Clavel F; Tjonneland A; Olsen A; Overvad K; Tetsche MS; Lund E; Lundin E; Berglund G; Riboli E; Kaaks R Endocr Relat Cancer; 2007 Mar; 14(1):81-90. PubMed ID: 17395977 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]